The Best of Exploration: Top 8 Stories of Space Exploration in 2012

Our recap of the year’s best exploratory exploits continues today with a look at the biggest developments in space exploration. 2012 saw the stunning debut of new spacecraft (Curiosity), the continued contributions of geriatric ones (Voyager), and the first full year since the end of the Space Shuttle program. Casey Dreier of The Planetary Society nominated 8 particularly meaningful developments from the last twelve months.



Image: Dreier’s pick for image of the year, a Cassini photograph of Saturn’s north pole through an infrared filter. (Credit: NASA / JPL / SSI / Emily Lakdawalla)


Read More..

Is Tom Cruise still a go-to action hero? Hollywood, “Jack Reacher” say yes






LOS ANGELES (TheWrap.com) – Given his age and the tough year he’s had in the tabloids, is Tom Cruise still a go-to guy when Hollywood is looking for an action hero?


The answer is yes, based on the performance of his current movie, Paramount‘s “Jack Reacher.” It’s taken in $ 45 million in the 10 days since opening with $ 15.6 million in a very crowded and competitive holiday market. Its second week was a solid $ 14 million, and it’s added $ 22 million from overseas.






Holiday movies tend to have legs and “Reacher” has yet to roll out in the majority of major foreign territories, so both of those numbers, particularly the international, will be growing. All signs point to it surpassing $ 200 million at the worldwide box office. That’s not a blockbuster figure, and Paramount is staying mum on a sequel, but with a $ 60 million budget, “Jack Reacher” will make money for Paramount.


There were questions coming in. With his divorce from Katie Holmes and subsequent custody battle, Cruise is carrying plenty of public relations baggage. His foray earlier this year into musicals with “Rock of Ages” was critically applauded but proved a box-office dud. That’s on top of his well-known support for Scientology.


He’s 50 now, which might be the new 40 in the real world, but is starting to get on in years in the realm of action heroes. Daniel Craig is 44. Jeremy Renner is 41. We are a long way from “Top Gun” – that was 1986 – so it probably won’t be too, too long until “The Expendables” franchise comes calling for Cruise.


But in the meantime, “Reacher” is going to be profitable for Paramount and Cruise’s portrayal of the tough, ex-military drifter has drawn critical kudos, so there’s a bit of momentum now. And it’s clear from his upcoming schedule that Hollywood is still convinced he can carry an action film.


Next for Cruise will be two sci-fi movies: Universal’s “Oblivion” is due in April and “All You Need is Kill” is set for March 2014 from Warner Bros. After that, there’s a potential “Van Helsing” remake at Universal and “Mission: Impossible 5″ is on Paramount‘s 2015 slate.


His recent track record at the box office, particularly when you look at his performance in the action genre, suggests the studios are making a pretty good bet.


“Rock of Ages” may have crumpled, but “Mission: Impossible – Ghost Protocol” was a huge hit for Paramount, taking in nearly $ 700 million worldwide in 2011. “Knight & Day,” from Fox in 2010, and “Valkyrie,” from United Artists in 2008, both made over $ 200 million worldwide.


Supporting roles in “Tropic Thunder” and “Lions for Lambs” preceded those, but those came on the heels of two Paramount movies: “Mission Impossible 3,” which made nearly $ 400 million worldwide in 2006, and “War of the Worlds,” which did $ 592 million in the previous year.


The bottom line: Hollywood is still convinced you can still take Tom Cruise, movie action hero, to the bank.


Movies News Headlines – Yahoo! News





Title Post: Is Tom Cruise still a go-to action hero? Hollywood, “Jack Reacher” say yes
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

F.D.A. Approves Sirturo, a New Tuberculosis Drug





The Food and Drug Administration announced on Monday that it had approved a new treatment for multidrug-resistant tuberculosis that can be used as an alternative when other drugs fail.




The drug, to be called Sirturo, was discovered by scientists at Janssen, the pharmaceuticals unit of Johnson & Johnson, and is the first in a new class of drugs that aims to treat the drug-resistant strain of the disease.


Tuberculosis is a highly infectious disease that is transmitted through the air and usually affects the lungs but can also affect other parts of the body, including the brain and kidneys. It is considered one of the world’s most serious public health threats. Although rare in the United States, multidrug-resistant tuberculosis is a growing problem elsewhere in the world, especially in poorer countries. About 12 million people worldwide had tuberculosis in 2011, according to Johnson & Johnson, and about 630,000 had multidrug-resistant TB.


A study in September in The Lancet found that almost 44 percent of patients with tuberculosis in countries like Russia, Peru and Thailand showed resistance to at least one second-line drug, or a medicine used after another drug had already failed.


Treating drug-resistant tuberculosis can take years and can cost 200 times as much as treating the ordinary form of the disease


“This is quite a milestone in the story of therapy for TB,” Dr. Paul Stoffels, the chief scientific officer at Johnson & Johnson, said in an interview. He said the approval was the first time in 40 years that the agency had approved a drug that attacked tuberculosis in a different way from the current treatments on the market. Sirturo works by inhibiting an enzyme needed by the tuberculosis bacteria to replicate and spread throughout the body.


Sirturo, also known as bedaquiline, would be used on top of the standard treatment, which is a combination of several drugs. Patients with drug-resistant tuberculosis often must be treated for 18 to 24 months.


Even as it announced the approval, however, the F.D.A. also issued some words of caution.


“Multidrug-resistant tuberculosis poses a serious health threat throughout the world, and Sirturo provides much-needed treatment for patients who have don’t have other therapeutic options available,” Edward Cox, director of the office of antimicrobial products in the F.D.A.’s center for drug evaluation and research, said in a statement. “However, because the drug also carries some significant risks, doctors should make sure they use it appropriately and only in patients who don’t have other treatment options.”


The consumer advocacy group Public Citizen opposed approval in a letter to the F.D.A. in mid-December, saying that the results of a limited clinical trial showed that patients using bedaquiline were five times as likely to die than those on the standard drug regimen to treat the disease.


“Given that bedaquiline belongs to an entirely new class of drugs, it is entirely feasible that death in some cases was due to some unmeasured toxicity of the drug,” the letter said.


Sirturo carries a so-called black box warning for patients and health care professionals that the drug can affect the heart’s electrical activity, which could lead to an abnormal and potentially fatal heart rhythm. The warning also notes deaths in patients treated with Sirturo. Nine patients who received Sirturo died compared with two patients who received a placebo. Five of the deaths in the Sirturo group and all of the deaths in the placebo arm seemed to be related to tuberculosis, but no consistent reason for the deaths in the remaining Sirturo-treated patients could be identified.


Doctors Without Borders and the Bill and Melinda Gates Foundation, both active in the fight against tuberculosis and other global diseases, applauded the F.D.A.’s decision.


Jan Gheuens, interim director of the TB Program for the Gates Foundation, called it a “long-awaited event” and said the fight against TB had not benefited from new drugs in the way H.I.V. had. Beyond the benefits of the drug itself, he said the quick approval process could be a model for other drugs sorely needed in the developing world.


He also suggested, however, that more trials should be conducted to get a better understanding of the side effects that led to the black box warning.


The F.D.A. approved bedaquiline under an accelerated program that allows the agency to conditionally approve drugs that are viewed as filling unmet medical needs with less than the usual evidence that they work. The drug’s approval was based on studies that showed it killed bacteria more quickly than a control group taking the standard regimen, but it did not measure whether in the end patients actually fared better on bedaquiline. Johnson & Johnson will conduct larger clinical trials to investigate whether the drug performs as predicted.


In a statement responding to Public Citizen’s letter, a spokeswoman for Johnson & Johnson said the company was committed to supporting appropriate use of Sirturo and would “work to ensure Sirturo is used only where treatment alternatives are not available.”


Dr. Stoffels said the hope was that other new tuberculosis drugs would also be approved that, when used in combination with bedaquiline, could shorten and simplify the current standard of treatment. “That is still a long time away,” he acknowledged, but “this is a first step in a new regimen for TB.”


Read More..

Hillary Clinton hospitalized with blood clot after concussion









WASHINGTON -- Secretary of State Hillary Rodham Clinton was hospitalized in New York on Sunday after doctors discovered a blood clot stemming from her concussion, the State Department said.


Clinton, 65, has been out of the public eye for the better part of December, at first because of what the State Department said was a stomach virus and later because of the concussion, which she suffered after fainting at her Washington home.


According to a spokesman, the clot was discovered in the course of a follow-up exam for the concussion at New York Presbyterian Hospital. She is being treated with anticoagulants and will remain at the hospital for the next 48 hours so doctors can monitor her response to the medication.





“Her doctors will continue to assess her condition, including other issues associated with her concussion,” Clinton spokesman Philippe Reines said in a statement. “They will determine if any further action is required.”


The State Department had said earlier that Clinton was set to resume her normal office schedule this week.


Earlier this month, the former first lady and New York senator had cited her concussion in canceling her scheduled appearance before a congressional committee investigating the Sept. 11 attack on a U.S. diplomatic facility in Benghazi, Libya, that left four Americans dead, including the ambassador.


A separate high-level investigative panel issued a scathing report blaming the State Department for security lapses. Clinton took responsibility, writing to the congressional committee that she  accepted "every one" of the Accountability Review Board's 29 recommendations.


She also praised the board, saying it had offered "a clear-eyed look at serious, systematic challenges that we have already begun to fix." 


Some conservatives had accused her of faking her illness to avoid testifying before the committee -- an accusation that the State Department strenuously denied. 









Read More..

Wired Science's Top Image Galleries of the Year

Many of our most popular posts are image galleries, and this year our readers favorite collections included microscope photos, doomsday scenarios, auroras and lots of images of Earth from space.


The satellite image above of Brasilia is part of the most popular post of the year.


Above:

I think it's safe to say that our readers like looking at images of Earth from space almost as much as we do. Satellite imagery was the subject of four of Wired Science's 10 most popular galleries of 2012, with this gallery of planned cities topping the list.


See the full gallery.


Image: NASA/USGS

Read More..

Comedian Katt Williams arrested in LA






LOS ANGELES (AP) — Katt Williams, the comedian who has repeatedly found himself on the wrong side of the law, is out on bail after being arrested in Los Angeles on suspicion of child endangerment and possession of a stolen gun.


Police Officer Norma Eisenman says Williams was taken into custody Friday after the LA County Department of Children and Family Services did a welfare check at his home. Authorities found more than one firearm, one of which had been reported stolen.






Eisenman says the DCFS did not specify how many children lived at the home or whether they were removed.


The 41-year-old was arrested this month on a felony warrant related to a police chase. In November, he was accused of hitting a man on the head with a bottle during a fight.


Entertainment News Headlines – Yahoo! News





Title Post: Comedian Katt Williams arrested in LA
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Dr. Rita Levi-Montalcini, a Revolutionary in the Study of the Brain, Dies at 103


Fabio Campana/European Pressphoto Agency


Rita Levi-Montalcini, the Italian Nobel laureate, in 2007.







Dr. Rita Levi-Montalcini, a Nobel Prize-winning neurologist who discovered critical chemical tools that the body uses to direct cell growth and build nerve networks, opening the way for the study of how those processes can go wrong in diseases like dementia and cancer, died on Sunday at her home in Rome. She was 103.




Her death was announced by Mayor Gianni Alemanno of Rome.


“I don’t use these words easily, but her work revolutionized the study of neural development, from how we think about it to how we intervene,” said Dr. Gerald D. Fishbach, a neuroscientist and professor emeritus at Columbia.


Scientists had virtually no idea how embryo cells built a latticework of intricate connections to other cells when Dr. Levi-Montalcini began studying chicken embryos in the bedroom of her house in Turin, Italy, during World War II. After years of obsessive study, much of it at Washington University in St. Louis with Dr. Viktor Hamburger, she found a protein that, when released by cells, attracted nerve growth from nearby developing cells.


In the early 1950s, she and Dr. Stanley Cohen, a biochemist also at Washington University, isolated and described the chemical, known as nerve growth factor — and in the process altered the study of cell growth and development. Scientists soon realized that the protein gave them a new way to study and understand disorders of neural growth, like cancer, or of degeneration, like Alzheimer’s disease, and to potentially develop therapies.


In the years after the discovery, Dr. Levi-Montalcini, Dr. Cohen and others described a large family of such growth-promoting agents, each of which worked to regulate the growth of specific cells. One, called epidermal growth factor and discovered by Dr. Cohen, plays a central role in breast cancer; in part by studying its behavior, scientists developed drugs to combat the abnormal growth.


In 1986, Dr. Levi-Montalcini and Dr. Cohen shared the Nobel Prize in Physiology or Medicine for their work.


Dr. Cohen, now an emeritus professor at Vanderbilt University, said Dr. Levi-Montalcini possessed a rare combination of intuition and passion, as well as biological knowledge. “She had this feeling for what was happening biologically,” he said. “She was an intuitive observer, and she saw that something was making these nerve connections grow and was determined to find out what it was.”


One of four children, Rita Levi-Montalcini was born in Turin on April 22, 1909, to Adamo Levi, an engineer, and Adele Montalcini, a painter, both Italian Jews who traced their roots to the Roman Empire. In keeping with the Victorian customs of the time, Mr. Levi discouraged his three daughters from entering college, fearing that it would interfere with their lives as wives and mothers.


It was not a future that Rita wanted. She had decided to become a doctor and told her father so. “He listened, looking at me with that serious and penetrating gaze of his that caused me such trepidation,” she wrote in her autobiography, “In Praise of Imperfection” (1988). He also agreed to support her.


She graduated summa cum laude from the University of Turin medical school in 1936. Two years later, Mussolini issued a manifesto barring non-Aryan Italians from having professional careers. She began her research anyway, setting up a small laboratory in her home to study chick embryos, inspired by the work of Dr. Hamburger, a prominent researcher in St. Louis who also worked with the embryos.


During World War II, the family fled Turin for the countryside, and in 1943 the invasion by Germany forced them to Florence. The family returned at the close of the war, in 1945, and Dr. Hamburger soon invited Dr. Levi-Montalcini to work for a year in his lab at Washington University.


She stayed on, becoming an associate professor in 1956 and a full professor in 1958. In 1962, she helped establish the Institute of Cell Biology in Rome and became its first director. She retired from Washington University in 1977, becoming a guest professor and splitting her time between Rome and St. Louis.


Italy honored her in 2001 by making her a senator for life.


An elegant presence, confident and passionate, she was a sought-after speaker until late in life. “At 100, I have a mind that is superior — thanks to experience — than when I was 20,” she said in 2009.


She never married and had no children. In addition to her autobiography, she was the author or co-author of dozens of research studies and received numerous professional awards, including the National Medal of Science.


“It is imperfection — not perfection — that is the end result of the program written into that formidably complex engine that is the human brain,” Dr. Levi-Montalcini wrote in her autobiography, “and of the influences exerted upon us by the environment and whoever takes care of us during the long years of our physical, psychological and intellectual development.”


This article has been revised to reflect the following correction:

Correction: December 30, 2012

An earlier version of this obituary misstated the year Mussolini issued a manifesto barring non-Aryan Italians from having professional careers. It was 1938, not 1936.



Read More..

Webster, N.Y., sniper's ex-neighbor charged with buying him guns









WASHINGTON — A former neighbor of the Webster, N.Y., sniper who killed two volunteer firefighters on Christmas Eve illegally bought the guns used in the killing, federal authorities charged Friday.


Dawn M. Nguyen, 24, of Greece, N.Y., was charged in federal court with acting as a straw purchaser for William Spengler, who as a felon could not legally buy guns for himself. Spengler was convicted of killing his grandmother in 1980. Nguyen also faces state felony charges on allegations of falsifying business records.


U.S. Atty. William J. Hochul Jr. said Nguyen purchased a Bushmaster .223 semiautomatic rifle and a Mossberg 12-gauge shotgun from the Gander Mountain store in Rochester on June 6, 2010. But in truth, he said, she "knowingly made a false statement in connection with the purchase of the two firearms" and actually was acquiring them for Spengler.





She did not immediately enter a plea in the more serious federal case, in which she could face 10 years in prison and a $250,000 fine.


Spengler fatally shot himself after killing volunteer firefighters Michael Chiapperini and Tomasz Kaczowka and wounding two other firefighters and an off-duty police officer.


Authorities say Spengler created a ruse by setting his car on fire in a blaze that spread to his home and six other houses on Lake Road in Webster. Spengler then opened fire on the emergency crew as they arrived at the neighborhood on the shore of Lake Ontario.


Sean J. Martineck, a special agent with the federal Bureau of Alcohol, Tobacco, Firearms and Explosives, said in a court affidavit that authorities learned of Nguyen from a suicide note Spengler left behind in which he said he obtained the weapons from his neighbor's daughter.


Nguyen lived next door to Spengler in 2008, two years after he was paroled from prison for killing his grandmother.


When officials spoke with Nguyen, Martineck said, she admitted that Spengler accompanied her to the gun shop and that he "picked out the firearms Nguyen purchased." But she said she wanted the weapons for her own personal safety and that they later were stolen from her vehicle. She never reported them stolen, however.


Finally, Martineck said, Nguyen "admitted that she purchased the guns for the guy who was her old neighbor," even though on the federal purchase form she had stated the weapons were for her own use.


richard.serrano@latimes.com





Read More..

So Last Year: RIM Dumps Cloud Hosting Acquisition











Last year, RIM — maker of the BlackBerry smartphone line — acquired NewBay, a cloud hosting service, for $100 million. But on Friday, Synchronoss, a mobile software company, announced that it is buying NewBay from RIM for $55 million cash.


The New Bay acquisition was seen as a way for RIM to compete with other file hosting and sync services, such as Apple iCloud, Amazon Cloud Drive, and Google Docs (now Google Drive). File sync services were hot at the time. Box was rumored to have turned down a $500,000+ acquisition deal, and Dropbox reportedly turned down a nine-figure acquisition offer from Apple. And Citrix acquired ShareFile, a lesser-known player.


RIM had been acquiring companies like contact management firm Gist and appointment management tool Tungle, suggesting the company was building out a stack of cloud-based mobile apps that would be independent of its own BlackBerry line. Meanwhile, rumor spread that the company would release a cross-platform version of BlackBerry Messenger as competing services like Beluga, GroupMe, and Kik began to challenge the product’s dominance.


As RIM bled market share to Apple and Samsung, these moves suggested that RIM could save itself by becoming a hardware-agnostic mobile software company. That hasn’t happened.


Although RIM began supporting Android and iOS on its popular BlackBerry Enterprise Server, the device management market has dozens of other players, including Good, which actually licenses RIM technology, and Microsoft, which has only recently joined the fray. And RIM shuttered both Gist and Tungle earlier this year to focus on developing similar BlackBerry-only products, and denies that a cross-platform version is on the roadmap.


With the sale of NewBay, it appears any hope for a cross-platform RIM is dead.






Read More..

Fans to join Beyonce onstage at Super Bowl






NEW YORK (AP) — All the single ladies — and fellas — will have a chance to join Beyonce onstage at the upcoming Super Bowl.


Pepsi announced Friday that 100 fans will hit the stage when the Grammy-winning diva performs on Feb. 3 at the Mercedes-Benz Superdome in New Orleans. A contest that kicks off Saturday will allow fans to submit photos of themselves in various poses, including head bopping, feet tapping and hip shaking. Those pictures will be used in a TV ad introducing Beyonce’s halftime performance, and 50 people — along with a friend — will be selected to join the singer onstage.






The photo contest — at www.pepsi.com/halftime — ends Jan. 19, but Jan. 11 is the cut-off date for those interested in appearing onstage with Beyonce.


Entertainment News Headlines – Yahoo! News





Title Post: Fans to join Beyonce onstage at Super Bowl
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..